Market open
Novavax/$NVAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Ticker
$NVAX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
952
ISIN
US6700024010
Website
Novavax Metrics
BasicAdvanced
$965M
2.00
$2.99
3.21
-
Price and volume
Market cap
$965M
Beta
3.21
52-week high
$23.86
52-week low
$5.01
Average daily volume
8.7M
Financial strength
Current ratio
2.056
Quick ratio
1.783
Long term debt to equity
-295.045
Total debt to equity
-302.287
Interest coverage (TTM)
19.68%
Management effectiveness
Return on assets (TTM)
20.27%
Return on equity (TTM)
-101.65%
Valuation
Price to earnings (TTM)
1.996
Price to revenue (TTM)
0.747
Price to book
-12.76
Price to tangible book (TTM)
-5.14
Price to free cash flow (TTM)
-4.728
Growth
Revenue change (TTM)
25.91%
Earnings per share change (TTM)
-185.53%
3-year revenue growth (CAGR)
-3.65%
3-year earnings per share growth (CAGR)
-44.55%
What the Analysts think about Novavax
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Novavax stock.
Novavax Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Novavax Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Novavax News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Novavax stock?
Novavax (NVAX) has a market cap of $965M as of May 15, 2025.
What is the P/E ratio for Novavax stock?
The price to earnings (P/E) ratio for Novavax (NVAX) stock is 2 as of May 15, 2025.
Does Novavax stock pay dividends?
No, Novavax (NVAX) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Novavax dividend payment date?
Novavax (NVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Novavax?
Novavax (NVAX) has a beta rating of 3.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.